Physician profile
Khalid Minhas
NPI 1093925539
$900.29
in general payments reported to CMS, 2019-2025
15 companies · $183 in 2025
The $183 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $40.72 · 2022: $50.54 · 2023: $18.79 · 2024: $478 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.10 | 2019-2025 | Lifevest |
| Pfizer INC. | $134.75 | 2024 | |
| Boston Scientific Corporation | $128.77 | 2022-2025 | Watchman Flx |
| Medtronic, INC. | $91.48 | 2024 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $74.77 | 2023-2024 | Camzyos |
| Novartis Pharmaceuticals Corporation | $55.31 | 2024 | |
| Janssen Pharmaceuticals, INC | $50.50 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $24.98 | 2024 | Arcalyst |
| Novo Nordisk INC | $23.02 | 2024 | Rybelsus, Ozempic |
| Terumo Medical Corporation | $22.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.08 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $17.05 | 2024 | Farxiga |
| Medtronic Vascular, INC. | $16.60 | 2019 | |
| Cardiva Medical, INC. | $16.47 | 2022 | |
| Merck Sharp & Dohme LLC | $14.88 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.